NCT05621902Not yet recruiting
Web-based Symptom Monitoring and Survival in Advanced Stage Lung Cancer
Source: ClinicalTrials.gov · Last updated 18 Nov 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to investigate if weekly symptom monitoring of patients with advanced lung cancer is associated with better survival and improved quality of life compared to standard follow-up. Each week, participants in the intervention group will be asked to respond to an electronic weekly questionnaire covering 11 items related to current health status.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 398 (estimated)
- First submitted
- 4 Nov 2022
- Start date
- 18 Nov 2022
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Mats Lambe
- Diseases
- Lung cancer
- NCT number
- NCT05621902
What you commit to
- Study type: Interventional
- Planned participants: 398
- From 18 Nov 2022 to the primary completion date, 30 Jun 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Treatment or disease which, according to the investigator, can affect treatment or study results
Other
- Symptomatic brain metastases
- Pregnancy, breastfeeding, or planned pregnancy
- Persons under guardianship or deprived of liberty
- Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation
- Ongoing participation in another interventional clinical study
Who the study is looking for
- Histologically or cytology proven non-small cell lung cancer (NSCLC)
- NSCLC stage III or IV
- ≥ 18 years
- ECOG performance status 0- 2
- Eligible patients should have initiated first-line treatment for advanced or metastatic disease with chemotherapy and/or immunotherapy, radiochemotherapy or targeted treatment
- Patients are eligible for inclusion if they have responded to first-line treatment with stable disease, or better, at the first radiological evaluation performed up to six months after start of treatment
- Stable disease, or better, on radiological assessment within 28 days of enrolment (CT scan or FDG-PET/CT. Cerebral MRI if known brain metastasis)
- Initial web-based application score of ≤ 6
- Basic computer literacy
- Bank-ID (electronic identification system) and access to "1177 Vårdguiden"
- The subject has given written consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.